Peptide Atlas · Peptide

Liraglutide

Liraglutide is a glucagon-like peptide-1 analogue given by once-daily subcutaneous injection.

established

provisional
PubChem 16134956
2 citations
0 discussions
0 followers
Arg34-Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37)
NN2211
Saxenda
Victoza

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Liraglutide. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
SCALE: 56-week randomized trial of liraglutide 3.0 mg in weight management	established	pmid 26132939
LEADER cardiovascular outcomes trial	established	pmid 27295427

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.